1. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56
- Author
-
Kerry Dobbs, Giovanna Tabellini, Enrica Calzoni, Ornella Patrizi, Paula Martinez, Silvia Clara Giliani, Daniele Moratto, Waleed Al-Herz, Caterina Cancrini, Morton Cowan, Jacob Bleesing, Claire Booth, David Buchbinder, Siobhan O. Burns, Talal A. Chatila, Janet Chou, Vanessa Daza-Cajigal, Lisa M. Ott de Bruin, Maite Teresa de la Morena, Gigliola Di Matteo, Andrea Finocchi, Raif Geha, Rakesh K. Goyal, Anthony Hayward, Steven Holland, Chiung-Hui Huang, Maria G. Kanariou, Alejandra King, Blanka Kaplan, Anastasiya Kleva, Taco W. Kuijpers, Bee Wah Lee, Vassilios Lougaris, Michel Massaad, Isabelle Meyts, Megan Morsheimer, Benedicte Neven, Sung-Yun Pai, Nima Parvaneh, Alessandro Plebani, Susan Prockop, Ismail Reisli, Jian Yi Soh, Raz Somech, Troy R. Torgerson, Yae-Jaen Kim, Jolan E. Walter, Andrew R. Gennery, Sevgi Keles, John P. Manis, Emanuela Marcenaro, Alessandro Moretta, Silvia Parolini, Luigi D. Notarangelo, AII - Inflammatory diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, and AII - Amsterdam institute for Infection and Immunity
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,Immunology ,chemical and pharmacologic phenomena ,Biology ,CD16 ,Regenerative Medicine ,Recombination-activating gene ,non-homologous end joining ,03 medical and health sciences ,Interleukin 21 ,Rare Diseases ,Immune system ,Stem Cell Research - Nonembryonic - Human ,interferon-γ ,Genetics ,medicine ,Immunology and Allergy ,recombinase-activating genes ,Original Research ,degranulation ,Transplantation ,Severe combined immunodeficiency ,Recombinase activity ,natural killer cells ,Degranulation ,Correction ,hemic and immune systems ,Stem Cell Research ,medicine.disease ,3. Good health ,030104 developmental biology ,Perforin ,Medical Microbiology ,biology.protein ,interferon-gamma ,CD56 ,lcsh:RC581-607 ,immunodeficiency - Abstract
Mutations of the recombinase-activating genes 1 and 2 (RAG1 and RAG2) in humans are associated with a broad range of phenotypes. For patients with severe clinical presentation, hematopoietic stem cell transplantation (HSCT) represents the only curative treatment; however, high rates of graft failure and incomplete immune reconstitution have been observed, especially after unconditioned haploidentical transplantation. Studies in mice have shown that Rag-/-natural killer (NK) cells have a mature phenotype, reduced fitness, and increased cytotoxicity. We aimed to analyze NK cell phenotype and function in patients with mutations in RAG and in non-homologous end joining (NHEJ) genes. Here, we provide evidence that NK cells from these patients have an immature phenotype, with significant expansion of CD56(bright) CD16(-/int) CD57(-cells), yet increased degranulation and high perforin content. Correlation was observed between in vitro recombinase activity of the mutant proteins, NK cell abnormalities, and in vivo clinical phenotype. Addition of serotherapy in the conditioning regimen, with the aim of depleting the autologous NK cell compartment, may be important to facilitate engraftment and immune reconstitution in patients with RAG and NHEJ defects treated by HSCT., Funding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. This work was also supported by grant 2R01AI100887 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (to JM). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
- Published
- 2017